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Abstract
One third of all stroke survivors develop post-stroke depression (PSD). Depressive symptoms
adversely affect rehabilitation and significantly increase risk of death in the post-stroke period.
One of the theoretical views on the determinants of PSD focuses on psychosocial factors like
disability and social support. Others emphasize biologic mechanisms such as disruption of
biogenic amine neurotransmission and release of proinflammatory cytokines. The “lesion
location” perspective attempts to establish a relationship between localization of stroke and
occurrence of depression, but empirical results remain contradictory. These divergences are partly
related to the fact that neuroimaging methods, unlike neuropathology, are not able to assess
precisely the full extent of stroke-affected areas and do not specify the different types of vascular
lesions. We provide here an overview of the known phenomenological profile and current
pathogenic hypotheses of PSD and present neuropathological data challenging the classic “single-
stroke”-based neuroanatomical model of PSD. We suggest that vascular burden due to the chronic
accumulation of small macrovascular and microvascular lesions may be a crucial determinant of
the development and evolution of PSD.
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1. Introduction
More than a hundred years ago, Meyer [1] postulated that depression may be the
consequence of the combined effect of brain injury, affecting mainly the left frontal lobe as
well as other lobar convexities, and psychosocial vulnerability such as past psychiatric
history. Although the association of depression with stroke has been recognized clinically
for several decades, only in the past 25 years systematic studies on this subject have been
conducted (for review see [2]). According to the World Health Organization [3], stroke is
the most common severe neurological disorder and the third leading cause of mortality
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among adults, with 15 million people worldwide suffering stroke annually. A recent review
reported a markedly stable frequency of depressive symptoms in 33% of all stroke survivors
at any time during the follow-up [4]. In addition, stroke survivors have more than six fold
higher risk of developing clinically overt depression even two or more years after index
stroke compared to age-matched controls [5]. Depression is significantly more likely after
stroke than other illnesses with comparable disability and adversely affects both short-term
recovery and long-term rehabilitation [6]. Moreover, death risk is three-fold higher over the
next decade in depressed stroke survivors compared to those without depression [7].
The possibility that the risk of depression after stroke is related to lesion location was
developed in the mid-seventies at John Hopkins University and originated the concept of
post-stroke depression (PSD) [8]. The first animal data in this field showed an association
between the laterality of brain damage after middle cerebral artery occlusion and both brain
catecholamine concentration and behavioral patterns in rats suggesting that the ischemic
damage may induce depression via the disruption of biogenic amine pathways [9]. Later on,
the first associations between the localization of stroke and occurrence of depression were
reported by the same group in humans [10]. Several subsequent studies suggested a link
between PSD and macrovascular lesions in various brain regions such as the left frontal
lobe, bilateral prefrontal cortex, left anterior and right occipital cortex (for review see [11]).
Despite these research efforts, the relationships between vascular lesions and the occurrence
of depression remain a matter of debate [12–14]. Equally intriguing are the recent
contradictory results on the location of brain lesions in PSD [8,11,15,16]. Methodological
issues such as differences in sampling, assessment interval from stroke and type of lesions
considered have been evoked to explain the discrepant results. After providing a brief
overview of the clinical, epidemiological and treatment issues related to PSD, the present
review focuses on the pathogenetic models of this condition and critically discusses its
neuroanatomical substrates with particular reference to the contribution of neuropathological
data in this field.
2. Clinical and epidemiological characteristics of PSD
The peak prevalence of major depression occurs 3–6 months after the stroke with a range of
9–34% during this time-frame [17]. The greatest increase in the prevalence of PSD is
observed between the initial and 1-month repeated assessments despite an overall decrease
of disability [18]. However, the risk appears to remain high even 1–3 years after stroke so
that if one considers all depressive episodes occurring both in the acute and later post-stroke
periods, PSD prevalence would be even higher reaching 25% to 79% [17]. Thus far, no
precise data are available regarding the impact of PSD on community healthcare resources
but it is thought that PSD patients are more often in institutional care, are more frequent
users of health services and show poorer functional recovery compared to non-depressed
stroke survivors [19]. Only physical disability, stroke severity and cognitive impairment
have been consistently identified as risk factors for PSD [20]. The depression-stroke Italian
multicenter study added female gender and previous cerebrovascular or depressive episodes
as significant risk factors for this condition [16]. More rarely cited psychosocial risk factors
include positive family history of anxiety or mood disorder, high trait neuroticism on the
Eysenck inventory, older age, bereavement, sleep disturbance, poor social support and
recent adverse life events [21].
Not surprisingly, a consensual definition of PSD is difficult to achieve [22]. Typically,
DSM-IV diagnostic criteria classify PSD within the group of “mood disorders due to stroke,
with depressive features” or “with major depressive-like episode” (DSM-IV, American
Psychiatric Association, 1994). Whyte and Mulsant [17] defined PSD as “depression
occurring in the context of a clinically apparent stroke (as opposed to silent vascular
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disease)” emphasizing the sequential nature of the two temporally related events – stroke
followed by depression – although an etiopathogenetic relationship is not assumed. The
clinical patterns of PSD remain quite vague. Paradiso et al. indicated that early-onset PSD is
characterized by anxiety, loss of libido and feelings of guilt, whereas later-onset PSD is
more frequently associated with diurnal variation of mood and social isolation [23]. In an
attempt to delineate PSD from major depression, Gainotti et al. proposed that catastrophic
reactions, hyperemotionality and diurnal mood variation are more consistently associated
with PSD, suicidal thoughts and anhedonia being more frequent in endogenous depression
[24]. However, catastrophic reactions and altered emotional regulation have been described
in several neurological conditions with or without depression raising doubts about the
specificity of this cluster for defining PSD [2].
The course of PSD seems to be dependent on the timing of onset. Early onset depressive
episodes tend to have a shorter course with more probable spontaneous remission in
comparison to later-onset depressive episodes. Astrom et al. showed that, at 1 year, 60% of
the patients with early depression (0 to 3 months) had recovered and that those who had not
recovered at this follow-up had a high risk of developing chronic depression [25]. The
results of Andersen et al. confirmed this notion showing that stroke survivors who
experience onset of depression seven weeks or later after their stroke have a lower rate of
spontaneous recovery [26]. There may be different biological or psychological processes
working in acute PSD in comparison to subacute or chronic mood disorder. Early PSD may
represent a transient reaction to the stroke with remission based on neural regeneration or
biochemical mechanisms (changes in receptor regulation, rate of transmitter or enzyme
synthesis). In contrast, late PSD may reflect neuropathological changes secondary to the
stroke with a delayed but enduring impact on mood [27].
3. Pharmacotherapy in PSD
Several placebo-controlled, randomized double-blind studies support the efficacy of
antidepressant medication in PSD. Citalopram [28], nortriptyline [29], and fluoxetine [30]
were all reported to be significantly more efficacious than placebo in the treatment of
depressive symptoms after stroke. The two latter agents also improved activities of daily
living [31] and reduced mortality [32]. Similarly, sertraline showed to be superior to placebo
in preventing the occurrence of PSD [33]. Besides its direct effect on depressive symptoms,
antidepressant treatment in PSD may also exert outcome-improving effects on the brain in at
least two ways [34]. An action on monoaminergic nuclei modulating cortico-striato-pallido-
thalamo-cortical (CSPTC) pathways is one of the options. Five CSPTC pathways referred to
as the oculomotor, dorsolateral prefrontal, lateral orbital frontal and anterior cingulated
pathways form closed loops, which originate from the prefrontal cortex and project to the
globus pallidus, substantia nigra and thalamus [35]. The last three pathways are involved in
both executive functions and affective regulation. Their functionality is thought to be closely
modulated by the activity of monoaminergic nuclei (namely, raphe, locus coeruleus and
ventral tegmental area) which are preferential sites of action of antidepressant medication
[36]. Alternatively, antidepressants may promote the secretion of neurotrophins favoring
brain recovery. One of these neurotrophins, brain-derived neurotrophic factor (BDNF), and
its receptor trkB, are increased by antidepressant treatment and it has been shown that
BDNF-dependent signaling, affecting intracellular signal transduction and synaptic
connectivity, is required for antidepressants to induce mood recovery [37]. One should,
however, keep in mind that the positive impact of antidepressants in PSD is not generally
accepted. For instance, a recent systematic review of pharmacological treatments in PSD
was unable to find any strong evidence on the effectiveness of pharmacotherapy in either
producing a remission or preventing the onset of depression after stroke [38].
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4. Impact of biological and psychosocial factors on PSD pathogenesis
Research into the pathogenesis of PSD is characterized by the striking opposition between
two theoretical models: that of the psychosocial vulnerability and that of the biological
determinism. This polarity of thought may have impeded the development of a
comprehensive approach to PSD prevention and treatment. In this section we will attempt to
explore both the relative impact and conceptual limits of each hypothesis.
4.1. Psychosocial vulnerability
The notion that depression in stroke patients involves the psychosocial response to disability
and loss has been present from the pioneer reports on emotional disorders following stroke.
Considering the brain as “the most cherished organ of humanity”, Fisher considered
depression an understandable reaction to cerebrovascular disease [39]. The relationship
between PSD and disability is complex since bidirectional causality has been sustained.
Disability after stroke may trigger PSD which in turn led to reduced functional outcome
[19,29,40]. Astrom et al. showed that several psychosocial factors play a role in the
development of both early and late-onset PSD [25]. The absence of family support is a
strong determinant of acute depressive reactions following stroke. Dependence for the
activities of daily living (ADL) is not associated with acute depressive reactions but it
becomes the most important predictor of depression after the first three months. This
observation may support the notion that functional impairment does not determine the onset
of depression but rather interacts with it to limit the results of long-term rehabilitation. One
year post-stroke, the persistence of few social contacts is the main psychosocial factor
associated with PSD. In the same line, during the 3 years following stroke depressed patients
have a marked paucity of social contacts compared to non-depressed patients. Although
these data point to the influence of psychosocial determinants in the development of PSD,
one should acknowledge that the distinction between dependent and independent variables is
quite ambiguous in this context (i.e. reduced social contacts can be a cause as well as a result
of depression).
4.2. Biological determinism
The biogenic amine and cytokine hypotheses represent the two main theories surrounding a
biological origin of PSD [41]. Robinson and Bloom postulated that ischemic lesions may
interrupt the biogenic amine-containing axons ascending from the brainstem to the cerebral
cortex leading to a decreased production of serotonin (5HT) and norepinephrine (NE) in
limbic structures of frontal and temporal lobes as well as basal ganglia [42]. The deficit of
biogenic amines in these areas or the failure to up-regulate 5HT receptors after stroke may
trigger PSD [43]. Supporting this hypothesis, significantly lower CSF concentrations of the
serotonin metabolite 5-hydroxy-indoleacetic acid were measured in PSD patients compared
to non-depressed stroke survivors [44]. Equally in line are the recent PET-scan findings of
Moller et al. [45] on 5HT1A receptor availability after stroke suggesting that changes of
serotonin neurotransmission may occur in the early phase of stroke and be modulated by
treatment with serotonin reuptake inhibitors (SSRI). In another study [46], growth hormone
(GH) response to desipramine was significantly blunted in PSD patients compared to non-
depressed post-stroke patients, suggesting diminished α2 adrenoreceptor function as a
possible marker of PSD.
Alternatively, the proinflammatory cytokines IL-1, tumor necrosis factor α (TNF-α), IL-6,
IL-8 and IL-18 that are involved in the initiation and amplification of the inflammatory
response to acute cerebral ischemia may also have depressiogenic properties. In fact, the
participation of proinflammatory cytokines in the etiology of depression has been explored
by several authors [47,48]. Interleukine-1β (IL-1β) and TNF-α can induce a depressive-like
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behavior in mice resembling the somatic syndrome of depression in humans. It is known that
autoimmune disorders and HIV, primarily affecting the immunological system, are
associated with depression. Additionally, increased brain levels of IL-1β, TNF-α, IL-6 have
been found in patients suffering from mood disorders [49]. Cytokine activation may induce
depressive symptoms by increasing the activity of the hypothalamus-pituitary-adrenal
(HPA) axis and altering biogenic amine neurotransmission in several hypothalamic nuclei as
well as limbic sites. Some cytokines are also known to up-regulate the tryptophane-
catabolizing enzyme indoleamine 2,3-deoxygenase (IDO) leading to decreased synthesis of
5HT. Although attractive, this hypothesis shows two main conceptual weaknesses. First, no
relationship was established between the level of proinflammatory cytokine induction and
PSD in humans. Most importantly, molecular cascades after stroke also include a marked
induction of anti-inflammatory cytokines which may counterbalance the depressiogenic
effect of proinflammatory cytokines [50,51].
5. Lesion location in PSD: the contribution of structural neuroimaging
After the pioneering work of Robinson and Szetela [52] who reported a significant inverse
correlation between the severity of PSD and distance of the anterior border of the lesion
from the frontal pole, several MRI studies attempted to explore the neuroanatomical
background of PSD leading to conflicting data. A first observation in this field concerns the
predominance of left hemisphere lesions in patients with PSD [10]. This right–left difference
was present both for cortical and subcortical lesions and seems to be more robust for left
anterior lesions [53]. More recent publications confirmed these findings suggesting the
existence of a significant relationship between PSD severity and proximity to the left frontal
pole (for review see [11]). However, the association between left anterior lesion location and
PSD is far from being consensual. Whereas Robinson’s pooling results [54] suggested that
left anterior cerebral lesions were associated with significantly higher depression scores than
left posterior lesions (the site of the lesion explaining 50% of the variance), two systematic
reviews by Singh et al. [55] and Carson et al. [8] did not support this association. The lack of
uniformity in definition and measurement of depression as well as sampling differences (i.e.,
in-patient versus community-based series) may partly explain these discrepancies. However,
the conflicting conclusions of different studies may be mostly attributed to the highly
variable assessment interval from the acute post-stroke period to the chronic stroke phase
[55]. In fact, it is conceivable that lesion location is a key determinant of PSD immediately
after stroke (namely by affecting biogenic amines and 5HT receptor function), while in late-
onset PSD failure to adapt to the consequences of stroke can be more important (through
impairments such as social isolation or visual perceptual decline and changes in arousal and
attention related to right hemisphere stroke). In this context, Shimoda and Robinson [56]
reported that, during the acute post-stroke period, PSD in inpatients was associated with left
anterior lesions. By 3–6 months post-stroke, the proximity of the lesion to the frontal pole in
both hemispheres rather than the hemispheric location influences the occurrence of PSD. At
this period, depression was also related to the impairment in daily living activities and social
functioning. At 1–2 years follow-ups, the occurrence of depression among the patients with
left hemisphere stroke was mostly determined by the severity of ADL impairment. At this
time period, depression in patients with right hemisphere damage was associated with lesion
volume and proximity to the occipital pole.
Undoubtedly, another parameter to consider is the strategic location of ischemic damage.
However, data in this field are scarce and contradictory probably reflecting the fact that
unlike neuropathology, most neuroimaging methods did not assess precisely the total extent
of the affected area. MRI-documented infarcts in hippocampus, basal ganglia and frontal
areas have been classically associated with PSD [57–59]. Hama et al. found that the severity
of affective depression was associated with left frontal lobe damage whereas apathetic
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depression was mostly related to basal ganglia damage [60]. In another study, the mean
frequency of infarcts in the genu of the internal capsule on the left side and bilateral
pallidum as well as the mean volume of infarcts in the right occipital lobe were independent
determinants of PSD [61].
6. Neuropathological substrates of PSD
Although difficult to perform, neuropathological analyses may be of great value in order to
assess the validity of the neuroanatomical model of PSD. Unlike structural imaging, they
allow for evaluating both the extent of vascular burden and different types of vascular
lesions in the human brain. In fact, as for vascular cognitive impairment, one could suspect
that not all vascular lesions had a deleterious impact on mood. In addition, they provide
reliable estimates of the number of small vascular lesions not easily identified by MRI. We
recently performed the only available neuropathological study of 95 consecutive autopsy
cases of patients with stroke [62]. Among them, there were 21 patients (9 men and 12
women) who developed PSD (mean age: 78.7±8.0 for men and 80.6±9.2 for women) and 74
(30 men and 44 women) patients without PSD (mean age: 83.5±7.2 for men and 86.5±5.4
for women). Clinical diagnosis of stroke was based on the presence of focal neurological
deficits of acute onset and supportive neuroimaging. Subjects with stroke were included
only if the diagnosis could be confirmed pathologically by the presence of cortical
macroinfarcts and if post-stroke survival was at least one month. Cases presenting with first-
onset depression more than 2 years after a stroke were excluded (4 cases). The clinical
diagnosis of depression was established prospectively using the DSM-IV criteria for major
and minor depression on the basis of the psychiatric examination performed by a specialist
in geriatric psychiatry. Lifetime history of depression was also established on the basis of
this interview. The diagnosis was confirmed in all cases after review of the medical records
by the same trained psychiatrist blind to the neuropathological findings. Both hemispheres
were cut into 1 cm thick coronal slices and examined for macroscopic vascular lesions
including brain infracts, cerebral hemorrhage or lacunar infarcts. Microscopic infarcts were
identified and dated on two adjacent sections of each level with hematoxylin–eosin and
cresyl violet stains. All cases with concurrent neuropathological evidence of Alzheimer’s
disease (Braak stages IV, V, and VI or dementia with Lewy bodies were excluded.
Macroscopic brain infracts, multiple lacunar infracts and substantial microvascular
pathology confined to one brain region were classified as focal ischemic pathology, whereas
multiple vascular lesions involving more than one cortical area were classified as multifocal
ischemic pathology. Our findings showed no relationship between the development of focal
and multifocal vascular pathology in a specific brain area and PSD in elderly patients
without lifetime history of depression. Among demographic variables, only younger age at
death was significantly related to PSD further confirming that depression after stroke is also
a predisposing factor for earlier death. Although these first neuropathological data could be
interpreted as an indirect support of the psychosocial model of PSD, several methodological
limitations should be taken into account. First, as is the case for all neuropathological
studies, autopsy-related biases cannot be excluded. Second, due to the limited number of
cases with PSD, the power of the present study does not permit to identify mild size effects.
Most importantly, this qualitative assessment mainly focused on macrovascular pathology
and did not include a detailed assessment of the brain microvascular burden.
7. Conclusions
Considering the discrepancies of neuroimaging studies about the link between lesion
location and PSD occurrence and our negative data in autopsy series, one could argue that
psychological rather than neurological factors are the main determinants of PSD. Such
statement may, however, be erroneous or at least premature. Paralleling the debate on the
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origin of PSD, the possible role of small macrovascular and microvascular lesions in
triggering depressive episodes has received further support in the late 90s when several
groups described a possible deleterious effect of MRI hyperintensities on affective
regulation. MRI hyperintensities referred to as leucoencephalopathy, leucoaraïosis and
subcortical encephalomalacia have been described both in depression and Alzheimer’s
disease [63] but also in normal brain aging [64]. They correspond to small vascular or
microvascular pathologic changes such as demyelination, cortical microinfarcts and lacunae
[65]. Usually associated with an increased vulnerability to cognitive impairment and
dementia [13,66], they gained significance in the pathogenesis of depression after the
introduction of the “vascular depression hypothesis” by Alexopoulos et al. [57]. Based on
the comorbidity of depressive syndromes with cerebrovascular lesions and cardiovascular
risk factors these authors postulated the existence of small macrovascular and microvascular
lesions affecting brain circuits responsible for mood control. Simultaneously, Krishnan et al.
described the clinical profile of vascular depression based on MRI observation of punctate
hyperintensities of the subcortical gray matter, deep white matter and periventricular regions
corresponding to vascularlesions [67]. Patients classified as having vascular depression on
MRI ratings were more likely to be elderly, nonpsychotic and to have a late-onset depressive
disorder. As concisely stated by Newberg et al. [68] “Overall, the concept of vascular
depression emphasizes the etiopathophysiologic relationship between cerebrovascular
lesions and depression while the concept of PSD emphasizes the temporal relationship
between the two”. In terms of etiopathogenesis, a progressive change of focus from
macroinfarcts to small vascular lesions has been already introduced by the concept of
“vascular cognitive impairment” in another highly debated field, that of the pathological
basis of vascular dementia. Our recent work in this field clearly demonstrates that some
microvascular lesions such as cortical microinfarcts, periventricular demyelination and
thalamic and basal ganglia lacunae may have an unexpected negative impact on cognitive
functions (for review see [69]). In a recently published article, Brodaty et al. proposed the
same change of focus for PSD stating that “depression after stroke may be related to
cumulative vascular brain pathology rather than side and severity of single stroke” [70]. In
this perspective, patients with chronic vascular burden could develop a PSD with a lower
rate of spontaneous recovery and higher risk of chronic depression compared to an early
PSD episode with spontaneous remission more probably associated with the location of
macrovascular stroke lesion. Further neuropathological studies in large and clinically well
characterized series are urgently needed to obtain a definite answer about the pertinence of
the neuroanatomical model of PSD.
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